ArticleMikrochimica acta2026
Exploitation of binary metal-organic framework embellished magnetic black phosphorus nanosheets for phosphoproteome analysis.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Binary metal-organic framework embellished magnetic black phosphorus nanosheets (Fe3O4/BPNSs/Ce-Zr MOF) were successfully prepared. This synthesis strategy avoided the traditional reliance on chelating agents and simplified the synthesis process. The physicochemical properties of Fe3O4/BPNSs/Ce-Zr MOF were systematically characterized by various means, such as transmission electron microscopy and X-ray diffraction analysis. The prepared material exhibited a high surface area, good hydrophilicity, and rapid magnetic responsiveness. Fe3O4/BPNSs/Ce-Zr MOF showed good affinity, which allowed the efficient capture of phosphopeptides from complex samples containing 5000-fold interfering peptides. Furthermore, Fe3O4/BPNSs/Ce-Zr MOF was applied to enrich phosphopeptides from more complicated biosamples, such as A549 cell lysate, highlighting its potential in phosphoproteomics applications.
Indexed as
Identifiers
42014577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.